Protara Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2024
Filed with the SEC on May 2, 2024 and accepted by EDGAR at May 2, 2024, 08:10 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2024-01-01 to 2024-03-31 | $7.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-01-01 to 2024-03-31 | −$11.9m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2024-01-01 to 2024-03-31 | −$11.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-01-01 to 2024-03-31 | −$0.97 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-01-01 to 2024-03-31 | −$0.97 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-01-01 to 2024-03-31 | 11,420,948 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2024-01-01 to 2024-03-31 | −$10.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Share repurchases | 3 months2024-01-01 to 2024-03-31 | $76.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2024-03-31 | $52.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-31 | $57.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-31 | $68.1m | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $5.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-03-31 | $9.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-03-31 | $58.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-24-038757. Last ingested by Listed: Nov 6, 2026, 12:14 ET. Listed shows no prices and gives no investment advice.